Updates on P53: Modulation of P53 Degradation As a Therapeutic Approach

Overview

Journal Br J Cancer

Specialty Oncology

Date 2008 Jan 10

PMID 18182973

Citations 22

Authors

A Dey

C S Verma

D P Lane

Affiliations

Soon will be listed here.

Abstract

The p53 pathway is aberrant in most human tumours with over 50% expressing mutant p53 proteins. The pathway is critically controlled by protein degradation. Here, we discuss the latest developments in the search for small molecules that can modulate p53 pathway protein stability and restore p53 activity for cancer therapy.

Citing Articles

Phosphorylation Regulates the Bound Structure of an Intrinsically Disordered Protein: The p53-TAZ2 Case.

Ithuralde R, Turjanski A PLoS One. 2016; 11(1):e0144284.

PMID: 26742101 PMC: 4712144. DOI: 10.1371/journal.pone.0144284.

Lentivirus‑delivered nemo‑like kinase small interfering RNA inhibits laryngeal cancer cell proliferation in vitro.

Tai J, Rao Y, Fang J, Huang Z, Yu Z, Chen X Mol Med Rep. 2015; 12(4):5619-24.

PMID: 26252054 PMC: 4581764. DOI: 10.3892/mmr.2015.4189.

Intraperitoneal delivery of a novel liposome-encapsulated paclitaxel redirects metabolic reprogramming and effectively inhibits cancer stem cells in Taxol(®)-resistant ovarian cancer.

Shen Y, Li W, Chen P, He C, Chang Y, Chuang C Am J Transl Res. 2015; 7(5):841-55.

PMID: 26175846 PMC: 4494136.

The oncolytic virus, pelareorep, as a novel anticancer agent: a review.

Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M Invest New Drugs. 2015; 33(3):761-74.

PMID: 25693885 DOI: 10.1007/s10637-015-0216-8.

DNA and RNA quadruplex-binding proteins.

Brazda V, Haronikova L, Liao J, Fojta M Int J Mol Sci. 2014; 15(10):17493-517.

PMID: 25268620 PMC: 4227175. DOI: 10.3390/ijms151017493.

References

Bertheau P, Plassa F, Espie M, Turpin E, de Roquancourt A, Marty M . Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 2002; 360(9336):852-4. DOI: 10.1016/S0140-6736(02)09969-5. View

Cheok C, Dey A, Lane D . Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res. 2007; 5(11):1133-45. DOI: 10.1158/1541-7786.MCR-07-0161. View

Rubbi C, Milner J . Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003; 22(22):6068-77. PMC: 275437. DOI: 10.1093/emboj/cdg579. View

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

Demidenko Z, Blagosklonny M . Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 2004; 64(10):3653-60. DOI: 10.1158/0008-5472.CAN-04-0204. View

Lane D, Hall P . MDM2--arbiter of p53's destruction. Trends Biochem Sci. 1997; 22(10):372-4. DOI: 10.1016/s0968-0004(97)01119-5. View

Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef L, Masucci M . Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med. 2004; 10(12):1321-8. DOI: 10.1038/nm1146. View

Bond G, Hu W, Levine A . MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005; 5(1):3-8. DOI: 10.2174/1568009053332627. View

Meulmeester E, Maurice M, Boutell C, Teunisse A, Ovaa H, Abraham T . Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell. 2005; 18(5):565-76. DOI: 10.1016/j.molcel.2005.04.024. View

10.

Yang Y, Ludwig R, Jensen J, Pierre S, Medaglia M, Davydov I . Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005; 7(6):547-59. DOI: 10.1016/j.ccr.2005.04.029. View

11.

Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P . Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 2005; 207(3):251-9. DOI: 10.1002/path.1838. View

12.

Kojima K, Konopleva M, Samudio I, Shikami M, Cabreira-Hansen M, McQueen T . MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005; 106(9):3150-9. PMC: 1895324. DOI: 10.1182/blood-2005-02-0553. View

13.

Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C . Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005; 106(10):3609-17. DOI: 10.1182/blood-2005-04-1489. View

14.

Krajewski M, Ozdowy P, DSilva L, Rothweiler U, Holak T . NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med. 2005; 11(11):1135-6. DOI: 10.1038/nm1105-1135. View

15.

Stevenson L, Sparks A, Allende-Vega N, Xirodimas D, Lane D, Saville M . The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 2007; 26(4):976-86. PMC: 1852834. DOI: 10.1038/sj.emboj.7601567. View

16.

Vousden K, Lane D . p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-83. DOI: 10.1038/nrm2147. View

17.

Joerger A, Fersht A . Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene. 2007; 26(15):2226-42. DOI: 10.1038/sj.onc.1210291. View

18.

Vogelstein B, Lane D, Levine A . Surfing the p53 network. Nature. 2000; 408(6810):307-10. DOI: 10.1038/35042675. View

19.

Lu W, Chen L, Peng Y, Chen J . Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene. 2001; 20(25):3206-16. DOI: 10.1038/sj.onc.1204412. View

20.

Li M, Chen D, Shiloh A, Luo J, Nikolaev A, Qin J . Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002; 416(6881):648-53. DOI: 10.1038/nature737. View